41
Participants
Start Date
July 31, 2013
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
Dacomitinib
Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
Dacomitinib
Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
Memorial Sloan-Kettering Cancer Center-Rockefeller Outpatient Pavilion, New York
Investigational Drug Service, Hillman Cancer Center, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
UPMC Hillman Cancer Center, Pittsburgh
Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Washington D.C.
Georgetown University Medical Center Department of Pharmacy, Research, Washington D.C.
UT Southwestern Medical Center, Dallas
UT Southwestern University Hospital - William P. Clements, Jr., Dallas
UT Southwestern University Hospital - Zale Lipshy, Dallas
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Tower Hematology Oncology Medical Group, Beverly Hills
UT Southwestern Medical Center-Simmons Cancer Center Pharmacy, Dallas
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Lead Sponsor
Pfizer
INDUSTRY